Traduction de «with » (Néerlandais → Français) :

TERMINOLOGIE

AERRPS - acute encephalitis with refractory repetitive partial seizures
syndrome épileptique par infection fébrile

CMDH - congenital muscular dystrophy with hyperlaxity
dystrophie musculaire congénitale avec hyperlaxité

TRADUCTIONS EN CONTEXTE

BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council
BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council

BAPCOC (with FPS Public Health) Board for biosafety (with WIV - ISP and the Biosafety and Biotechnology Service) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Professional Ethics Committee (with FPS Public Health - DG Animals - Plants - Foodstuffs) Strategic unit/RIZIV - INAMI
BAPCOC (with FPS Public Health) Board for biosafety (with WIV - ISP and the Biosafety and Biotechnology Service) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Professional Ethics Committee (with FPS Public Health - DG Animals - Plants - Foodstuffs) Strategic unit/RIZIV - INAMI

Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)
Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)

Ventralight ST with Echo PS – Ellipse 15,2 cm x 20,3 cm = 242,34 cm² 5955680 Ventralight ST with Echo PS – Ellipse 15,2 cm x 25,4 cm = 340,00 cm² 5955610 Ventralight ST with Echo PS – Ellipse 17,8 cm x 22,9 cm = 320,14 cm² 5955790 Ventralight ST with Echo PS – Ellipse 20,3 cm x 25,4 cm = 404,97 cm² 5955810 Ventralight ST with Echo PS – Ellipse 25,4 cm x 33 cm = 658,32 cm² 5955113 Ventralight ST with Echo PS – Ellipse 30,5 cm x 35,6 cm = 1.085,80 cm² 5955124
Ventralight ST with Echo PS – Ellipse 15,2 cm x 20,3 cm = 242,34 cm² 5955680 Ventralight ST with Echo PS – Ellipse 15,2 cm x 25,4 cm = 340,00 cm² 5955610 Ventralight ST with Echo PS – Ellipse 17,8 cm x 22,9 cm = 320,14 cm² 5955790 Ventralight ST with Echo PS – Ellipse 20,3 cm x 25,4 cm = 404,97 cm² 5955810 Ventralight ST with Echo PS – Ellipse 25,4 cm x 33 cm = 658,32 cm² 5955113 Ventralight ST with Echo PS – Ellipse 30,5 cm x 35,6 cm = 1.085,80 5955124 cm²

Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s
Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s

Consultation platform with FAVV - AFSCA, FPS Public Health e-MED (electronic prescription of medicines) (with FPS Public e-MED (electronic prescription of medicines) (with FPS Public
Consultation platform with FAVV - AFSCA, FPS Public Health e-MED (electronic prescription of medicines) (with FPS Public e-MED (electronic prescription of medicines) (with FPS Public

Regular consultation platforms with other government services and institutions such as: ●● BAPCOC (with FPS Public Health) ●● Board for biosafety (with WIV - ISP and the
Regular consultation platforms with other government services and institutions such as: ●● BAPCOC (with FPS Public Health) ●● Board for biosafety (with WIV - ISP and the

and Public Health Minister’s office “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS
and Public Health Minister’s office “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS

The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).JAMA 2002; 288: 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstline antihypertensive therapies : a meta-analysis of randomised controlled trials.
The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002 ; 288 : 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstlineantihypertensive therapies : a meta-analysis of randomised controlled trials.

JAMA 2002 ; 288 :2981-2997 (6) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other first-line antihypertensive therapies : a meta-analysis of randomised controlled trials.
JAMA 2002 ; 288 : 2981-2997 (6) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other first-line antihypertensive therapies : a meta-analysis of randomised controlled trials.